Analyst Ratings For NASDAQ:BIIB – Biogen (NASDAQ:BIIB)
Today, Citigroup lowered its price target on NASDAQ:BIIB – Biogen (NASDAQ:BIIB) to $290.00 per share.
Some recent analyst ratings include
- 4/26/2018-Cantor Fitzgerald Reiterated Rating of Neutral.
- 4/25/2018-Goldman Sachs Reiterated Rating of Conviction-Buy .
- 4/25/2018-Robert W. Baird Upgrade from a “Neutral ” rating to a ” Outperform” rating.
Recent Insider Trading Activity For NASDAQ:BIIB – Biogen (NASDAQ:BIIB)
NASDAQ:BIIB – Biogen (NASDAQ:BIIB) has insider ownership of 0.25% and institutional ownership of 89.00%.
- On 4/25/2018 Alexander J Denner, Director, bought 48,000 with an average share price of $269.91 per share and the total transaction amounting to $12,955,680.00.
- On 2/27/2018 Alfred Sandrock, EVP, sold 259 with an average share price of $290.83 per share and the total transaction amounting to $75,324.97.
- On 2/20/2018 Alfred Sandrock, EVP, sold 743 with an average share price of $292.00 per share and the total transaction amounting to $216,956.00.
- On 2/15/2018 Alfred Sandrock, EVP, sold 1,294 with an average share price of $298.85 per share and the total transaction amounting to $386,711.90.
- On 1/9/2018 Robert W Pangia, Director, sold 5,832 with an average share price of $329.65 per share and the total transaction amounting to $1,922,518.80.
- On 12/29/2017 Michel Vounatsos, CEO, bought 780 with an average share price of $320.55 per share and the total transaction amounting to $250,029.00.
- On 12/29/2017 Michel Vounatsos, CEO, bought 780 with an average share price of $320.55 per share and the total transaction amounting to $250,029.00.
Recent Trading Activity for NASDAQ:BIIB – Biogen (NASDAQ:BIIB)
Shares of NASDAQ:BIIB – Biogen closed the previous trading session at 266.05 down -8.56 3.12% with 274.2149963378906 shares trading hands.